Originally posted by JujuM
Owl, thank you for your opinion and for addressing Gooma's concern so eloquently.
For me, I see nothing wrong here in regard management and previous announcements. I see no reason for them to "pull their heads in".
The way I read it is that the deal with Prism was imminent. Then it became obvious that they were struggling operationally to execute. PIQ management rightly recognised that this was not in the company and shareholder's best interests and rescinded the deal, preferring to not have a failure at such a crucial juncture and to open up the option for a tier 1 partner to do what Prism was clearly struggling to deliver.
As a shareholder, I feel the pain in regard to the short term share price drop, however, as far as the big picture is concerned if PIQ does get a stronger partner who can deliver a faster rollout, the short term pain will be worth the long term gain
With respect to Gooma and his understandable frustration, I would rather look at what's actually going on rather than get stuck on the word 'imminent'. An imminent deal was changing to imminent failure. I would prefer Management to recognise that at the 11th hour and rescind, rather than them say "oh dear we said this deal was imminent so we can't change tack now even if it means failure". What has happened here is a no brainer. They disclosed a deal was imminent - they have to by law, the deal failed and they have announced so. Whats to pull their head in about?
Really, I can't believe that I am having to explain this but thank god management didn't pull theirs in and go ahead with a failing deal. Good on them for recognising the situation, sticking their heads up and rectifying the situation. It would have been disastrous otherwise.
If the bots and short term traders don't like it and react accordingly so be it. That's the market. Its made up of more than big picture long term investors. As a long term investor in PIQ I think it's realistic to expect the short term traders to react this way and devalue the stock, its got nothing to do with the management decision, it's got everything to do with the nature of the market.
Thanks Juju,
Wholeheartedly agree with your post. PIQ have been ticking the boxes. According to the ANN, there are 260,000 CLIA accredited laboratories in the USA, the majority of which have the capability of using PromarkerD with dual technologies. That’s the beauty of this, even if they don’t have mass spectrometry they are still able to utilise the ELISA test kit & have analysis done remotely. For me that’s a no brainer, not just in the USA.
it’s not like big laboratories don’t take M&A seriously. NASH is another disease on the rise:
https://www.bizjournals.com/triad/n...rench-biopharm-company-partner-to-create.html:
New drugs coming out for Endometriosis pain in the USA, another unmet clinical need PIQ are developing a test for & diagnosed by laporotomy & suspected on clinical symptoms. When this test in our pipeline is up & running, I think it will be huge & possibly may prevent exploratory surgery...there’s always a risk with anaesthetics & surgery...& early diagnosis means earlier treatment & possibly prevent infertility in younger women. 1:10 here in Australia.
https://www.fiercepharma.com/market...ads-target-women-endometriosis-symptoms-as-it
Whilst we have standard diabetes & kidney testing available, there is nothing that is going to predict it apart from PromarkerD, so yes a little too late when blood & urine tests are showing up as abnormal, especially in younger people, which is a damn shame.
Hopefully some of the bigger players can see the value in this, as obviously we both do. Clinical Trials included, not just diagnostics.
(20min delay)